tradingkey.logo

Evoke Pharma Inc

EVOK
查看详细走势图
11.000USD
0.000
收盘 12/19, 16:00美东报价延迟15分钟
18.95M总市值
亏损市盈率 TTM

Evoke Pharma Inc

11.000
0.000
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

0.00%

5天

+0.46%

1月

+2.90%

6月

+299.55%

今年开始到现在

+148.87%

1年

+116.96%

查看详细走势图

TradingKey Evoke Pharma Inc股票评分

单位: USD 更新时间: 2025-12-17

操作建议

Evoke Pharma Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在药品行业排名101/159位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价18.00。中期看,股价处于上升通道。近一个月,市场表现非常差,但公司基本面和技术面得分较高。

Evoke Pharma Inc评分

相关信息

行业排名
101 / 159
全市场排名
255 / 4587
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 1 位分析师
持有
评级
18.000
目标均价
+250.19%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Evoke Pharma Inc亮点

亮点风险
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
业绩高增长
公司营业收入稳步增长,连续3年增长308.56%
业绩增长期
公司处于发展阶段,最新年度总收入10.25M美元
估值合理
公司最新PE估值0.00,处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值18.76K
活跃度降低
近期活跃度降低,过去20天平均换手率-0.17

Evoke Pharma Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Evoke Pharma Inc简介

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
公司代码EVOK
公司Evoke Pharma Inc
CEOD'Onofrio (Matthew J)
网址https://evokepharma.com/

常见问题

Evoke Pharma Inc(EVOK)的当前股价是多少?

Evoke Pharma Inc(EVOK)的当前股价是 11.000。

Evoke Pharma Inc的股票代码是什么?

Evoke Pharma Inc的股票代码是EVOK。

Evoke Pharma Inc股票的52周最高点是多少?

Evoke Pharma Inc股票的52周最高点是10.990。

Evoke Pharma Inc股票的52周最低点是多少?

Evoke Pharma Inc股票的52周最低点是1.940。

Evoke Pharma Inc的市值是多少?

Evoke Pharma Inc的市值是18.95M。

Evoke Pharma Inc的净利润是多少?

Evoke Pharma Inc的净利润为-5.35M。

现在Evoke Pharma Inc(EVOK)的股票是买入、持有还是卖出?

根据分析师评级,Evoke Pharma Inc(EVOK)的总体评级为持有,目标价格为18.000。

Evoke Pharma Inc(EVOK)股票的每股收益(EPS TTM)是多少

Evoke Pharma Inc(EVOK)股票的每股收益(EPS TTM)是-1.379。
KeyAI